AP2238 was the first compound published to bind both anionic sites of the human acetylcholinesterase,allowing the simultaneous inhibition of the catalytic and the amyloid-
![](/images/gifchars/beta2.gif)
pro-aggregating activities of AChE.Here we attempted to derive a comprehensive structure-activity relationship picture for this molecule,affording 28 derivatives for which AChE and BChE inhibitory activities were evaluated. Selected compoundswere also tested for their ability to prevent the AChE-induced A
![](/images/gifchars/beta2.gif)
-aggregation. Moreover, docking simulationsand molecular orbital calculations were performed.